Predicting Factors of Fistula Healing and Clinical Remission After Infliximab-Based Combined Therapy for Perianal Fistulizing Crohn’s Disease

  • David Tougeron
  • Guillaume Savoye
  • Céline Savoye-Collet
  • Edith Koning
  • Francis Michot
  • Eric Lerebours
Original Article

Abstract

Perianal fistulizing Crohn’s disease (PFCD) treatment is based on fistula drainage, antibiotics, immunosuppressant (IS) drugs, and infliximab. Our aim was to study the effectiveness of combination therapy on PFCD and to search for clinical or imaging features associated with the initial complete clinical response and its stability overtime. Patients and methods All patients with PFCD treated in our tertiary center between 2000 and 2005 by infliximab in combination with seton placement and/or IS and evaluated by MRI before treatment were included in the study. Basal clinical and MRI characteristics were recorded. Response to treatment was evaluated after the infliximab induction regiment and at the end of the follow-up. Results Twenty-six patients were included and followed-up for an average 4.9 years. A complex fistula was present in 69% (18/26 patients) of cases and eight (8/26 patients) had an ano-vaginal fistula. After infliximab induction therapy, 13 patients (50%) achieved a complete clinical response. The initial clinical response was significantly associated with the absence of both, active intestinal disease (54% vs. 8%, P = 0.03) and active proctitis (77% vs. 23%, P = 0.01). No initial MRI characteristics were linked to the initial response. In multivariate analysis, only the presence of active proctitis was associated with the lack of response (P = 0.047). At the end of the follow-up, 42% of the patients remained in clinical remission. No clinical characteristics were associated to sustained response when among long-standing responders two exhibited a normal post-treatment MRI. Conclusion An initial complete response of PFCD was observed in half of the patients after combined therapy including infliximab that decreased to 42% later on. Complete healing of fistulas on MRI was possible but unusual. The initial response seemed related to the absence of active intestinal disease, especially in the rectum, when the long-term response could not be predicted by the basal characteristics of patients.

Keywords

Perianal Crohn’s disease Infliximab MR imaging 

References

  1. 1.
    Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130:650–656. doi:10.1053/j.gastro.2005.12.019.PubMedCrossRefGoogle Scholar
  2. 2.
    Gower-Rousseau C, Salomez JL, Dupas JL, et al. Incidence of inflammatory bowel disease in northern France (1988–1990). Gut. 1994;35:1433–1438. doi:10.1136/gut.35.10.1433.PubMedCrossRefGoogle Scholar
  3. 3.
    Molinie F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn’s disease and ulcerative colitis in Northern France (1988–1999). Gut. 2004;53:843–848. doi:10.1136/gut.2003.025346.PubMedCrossRefGoogle Scholar
  4. 4.
    Singh B, Mc C, Mortensen NJ, Jewell DP, George B. Perianal Crohn’s disease. Br J Surg. 2004;91:801–814. doi:10.1002/bjs.4613.PubMedCrossRefGoogle Scholar
  5. 5.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405. doi:10.1056/NEJM199905063401804.PubMedCrossRefGoogle Scholar
  6. 6.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885. doi:10.1056/NEJMoa030815.PubMedCrossRefGoogle Scholar
  7. 7.
    Ouraghi A, Nieuviarts S, Mougenel JL, et al. Infliximab therapy for Crohn’s disease anoperineal lesions. Gastroenterol Clin Biol. 2001;25:949–956.PubMedGoogle Scholar
  8. 8.
    Lichtenstein G, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128:862–869. doi:10.1053/j.gastro.2005.01.048.PubMedCrossRefGoogle Scholar
  9. 9.
    West RL, van der Woude CJ, Hansen BE, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20:1329–1336. doi:10.1111/j.1365-2036.2004.02247.x.PubMedCrossRefGoogle Scholar
  10. 10.
    Hyder SA, Travis S, Jewell D, Mortensen N, George B. Fistulating anal Crohn’s disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49:1837–1841. doi:10.1007/s10350-006-0656-5.PubMedCrossRefGoogle Scholar
  11. 11.
    Schwartz DA, Herdman CR. Review article: the medical treatment of Crohn’s perianal fistulas. Aliment Pharmacol Ther. 2004;19:953–967. doi:10.1111/j.1365-2036.2004.01917.x.PubMedCrossRefGoogle Scholar
  12. 12.
    Ochsenkuhn T, Goke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn’s disease. Am J Gastroenterol. 2002;97:2022–2025.PubMedGoogle Scholar
  13. 13.
    Schroder O, Blumenstein A, Schulte-Bockholt A, Stein J. Combining infliximab and methotrexate in fistulizing Crohn’s disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther. 2004;19:295–301. doi:10.1111/j.1365-2036.2004.01850.x.PubMedCrossRefGoogle Scholar
  14. 14.
    Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology. 1990;90:1347–1351.Google Scholar
  15. 15.
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med. 1995;123:132–142.PubMedGoogle Scholar
  16. 16.
    Topstad DR, Panaccione R, Heine JA, Johnson DRE, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease. A single center experience. Dis Colon Rectum. 2003;46:577–583. doi:10.1007/s10350-004-6611-4.PubMedCrossRefGoogle Scholar
  17. 17.
    Williams JG, Rothenberger DA, Nemer FD, Goldberg SM. Fistula-in ano in Crohn’s disease. Results of aggressive surgical treatment. Dis Colon Rectum. 1991;34:378–384. doi:10.1007/BF02053687.PubMedCrossRefGoogle Scholar
  18. 18.
    Ardizzone S, Maconi G, Colombo E, Bollani Sand MG, Bianchi Porro G. Perianal fistulae following infliximab treatment. Clinical and endosonographic outcome. Inflamm Bowel Dis. 2004;10:91–96. doi:10.1097/00054725-200403000-00005.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol. 2003;98:332–339.PubMedCrossRefGoogle Scholar
  20. 20.
    Loftus EV. Editorial imaging and therapy for perianal Crohn’s disease: on the right track? Am J Gastroenterol. 2004;99:89–90. doi:10.1111/j.1572-0241.2004.04016.x.PubMedCrossRefGoogle Scholar
  21. 21.
    Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology. 2002;123:707–713. doi:10.1053/gast.2002.35390.PubMedCrossRefGoogle Scholar
  22. 22.
    Parsi MA, Lashner BA, Achkar JP, Connor JT, Brzezinski A. Type of fistula determines responses to infliximab in patients with fistulous Crohn’s disease. Am J Gastroenterol. 2004;99:445–449. doi:10.1111/j.1572-0241.2004.04083.x.PubMedCrossRefGoogle Scholar
  23. 23.
    Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-TNF necrosis factor (infliximab) treatment on Crohn’s disease. Am J Gastroenterol. 2002;97:2357–2363. doi:10.1111/j.1572-0241.2002.05991.x.PubMedCrossRefGoogle Scholar
  24. 24.
    Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to examine under anaesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98–103. doi:10.1097/00054725-200303000-00003.PubMedCrossRefGoogle Scholar
  25. 25.
    Rasul I, Wilson SR, MacRae H, Irwin S, Greenberg GR. Clinical and radiological responses after infliximab treatment for perianal fistulising Crohn’s disease. Am J Gastroenterol. 2004;99:82–88. doi:10.1046/j.1572-0241.2003.04009.x.PubMedCrossRefGoogle Scholar
  26. 26.
    Bell SJ, Halligan AC, Windsor ACJ, Williams AB, Wiesel P, Kamm MA. Response of fistulating Crohn’s disease to infliximab treatment assessed by magnetic resonance. Aliment Pharmacol Ther. 2003;17:387–393. doi:10.1046/j.1365-2036.2003.01427.x.PubMedCrossRefGoogle Scholar
  27. 27.
    Schwartz DA, White CM, Wise PE, Herline AJ. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn’s perianal fistulas. Inflamm Bowel Dis. 2005;11:727–732. doi:10.1097/01.MIB.0000172811.57242.18.PubMedCrossRefGoogle Scholar
  28. 28.
    Rutgeerts P, Diamonds RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc. 2006;63:433–442. doi:10.1016/j.gie.2005.08.011.PubMedCrossRefGoogle Scholar
  29. 29.
    Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453–455. doi:10.1136/gut.2005.088732.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • David Tougeron
    • 1
  • Guillaume Savoye
    • 1
  • Céline Savoye-Collet
    • 2
  • Edith Koning
    • 2
  • Francis Michot
    • 3
  • Eric Lerebours
    • 1
  1. 1.Department of Gastroenterology and Hepatology, ADEN EA 4311Rouen University Hospital C NicolleRouenFrance
  2. 2.Radiology DepartmentRouen University Hospital C NicolleRouenFrance
  3. 3.Department of SurgeryRouen University Hospital C NicolleRouenFrance

Personalised recommendations